Polyp adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 6,449 adverse event reports that record the MedDRA preferred term Polyp. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 315 reports in the 12 months to June 2026 and 329 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,212 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 315 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 26% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 103 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Polyp name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	37
Accutane	Retinoid	71
Actemra	Interleukin-6 receptor antagonist	54
Advair Hfa	Corticosteroid	55
Albuterol	beta2-Adrenergic agonist	57
Albuterol sulfate	beta2-Adrenergic agonist	117
Alendronate sodium	Bisphosphonate	25
Altace		63
Amitriptyline		37
Amlodipine	Calcium channel blocker	53
Amlodipine besylate	Dihydropyridine calcium channel blocker	25
Aredia		27
Aspirin	Nonsteroidal anti-inflammatory drug	54
Atenolol	beta-Adrenergic blocker	49
Atorvastatin		39
Atorvastatin calcium	HMG-CoA reductase inhibitor	37
Avonex	Interferon beta	38
Benicar	Angiotensin 2 receptor blocker	217
Benicar HCT	Thiazide diuretic	160
Betahistine		34
Budesonide	Corticosteroid	92
Budesonide Formoterol Fumarate		40
Candesartan	Angiotensin 2 receptor blocker	67
Candesartan cilexetil	Angiotensin 2 receptor blocker	44
Ciclesonide		30
Clopidogrel	P2Y12 platelet inhibitor	40
Clopidogrel bisulfate	P2Y12 platelet inhibitor	57
Cosentyx	Interleukin-17A antagonist	52
Coumadin		31
Creon		31
Cymbalta		43
Detrol	Cholinergic muscarinic antagonist	35
Dupixent	Interleukin-4 receptor alpha antagonist	99
Eliquis	Factor Xa inhibitor	103
Enbrel	Tumor necrosis factor blocker	124
Entresto	Angiotensin 2 receptor blocker	26
Entyvio	Integrin receptor antagonist	45
Esomeprazole magnesium	Proton pump inhibitor	28
Forteo	Parathyroid hormone analog	36
Fosamax	Bisphosphonate	88
Furosemide	Loop diuretic	46
Gabapentin	Anti-epileptic agent	42
Human immunoglobulin g	Human immunoglobulin G	32
Humira		807
Hydrochlorothiazide	Thiazide diuretic	89
Imbruvica	Kinase inhibitor	60
Indapamide	Thiazide-like diuretic	41
Inflectra	Tumor necrosis factor blocker	67
Infliximab	Tumor necrosis factor blocker	54
Influenza virus vaccine		34
Iron		33
Lansoprazole	Proton pump inhibitor	62
Lipitor	HMG-CoA reductase inhibitor	46
Lorazepam	Benzodiazepine	43
Lyrica		30
Mepolizumab	Interleukin-5 antagonist	105
Metformin	Biguanide	77
Methotrexate	Folate analog metabolic inhibitor	120
Metoprolol	beta-Adrenergic blocker	25
Nexium	Proton pump inhibitor	144
Nucala	Interleukin-5 antagonist	55
Omalizumab	Anti-IgE	34
Omeprazole	Proton pump inhibitor	35
Omnaris		35
Pantoprazole	Proton pump inhibitor	27
Pradaxa	Direct thrombin inhibitor	61
Prednisone	Corticosteroid	225
Prilosec	Proton pump inhibitor	25
Pulmicort Turbuhaler		57
Rabeprazole	Proton pump inhibitor	32
Rabeprazole sodium	Proton pump inhibitor	52
Ramipril	Angiotensin converting enzyme inhibitor	85
Ranitidine	Histamine-2 receptor antagonist	40
Remicade	Tumor necrosis factor blocker	117
Revlimid	Thalidomide analog	55
Rinvoq	Janus kinase inhibitor	73
Risedronate sodium	Bisphosphonate	71
Rituximab	CD20-directed cytolytic antibody	42
Ropinirole	Nonergot dopamine agonist	25
Salbutamol		42
Salbutamol sulfate		39
Sandostatin	Somatostatin analog	114
Sandostatin LAR Depot		75
Singulair	Leukotriene receptor antagonist	60
Skyrizi	Interleukin-23 antagonist	98
Somavert		30
Stelara	Interleukin-12 antagonist	40
Symbicort	Corticosteroid	103
Synthroid	l-Thyroxine	47
Teduglutide	GLP-2 analog	46
Temazepam	Benzodiazepine	35
Tiotropium bromide	Anticholinergic	49
Tiotropium bromide monohydrate		32
Vedolizumab	Integrin receptor antagonist	60
Vioxx		69
Warfarin	Vitamin K antagonist	25
Xarelto	Factor Xa inhibitor	97
Xeljanz	Janus kinase inhibitor	89
Xolair	Anti-IgE	61
Xyrem	Central nervous system depressant	31
Zantac		41
Zenhale		53
Zometa		36

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 57 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Polyp name, in order of name
Class	Reports with this term
Angiotensin 2 receptor blocker	422
Angiotensin converting enzyme inhibitor	98
Anti-epileptic agent	51
Anti-IgE	95
Anticholinergic	69
Atypical antipsychotic	45
Benzodiazepine	85
beta-Adrenergic blocker	105
beta2-Adrenergic agonist	192
Biguanide	86
Bisphosphonate	209
Calcineurin inhibitor immunosuppressant	25
Calcium channel blocker	57
CD20-directed cytolytic antibody	92
Central nervous system depressant	33
Cholinergic muscarinic antagonist	35
Corticosteroid	604
Dihydropyridine calcium channel blocker	27
Direct thrombin inhibitor	61
Endothelin receptor antagonist	76
Factor Xa inhibitor	225
Folate analog metabolic inhibitor	136
GLP-1 receptor agonist	79
GLP-2 analog	57
Histamine-2 receptor antagonist	67
HMG-CoA reductase inhibitor	125
Human immunoglobulin G	36
Insulin analog	26
Integrin receptor antagonist	123
Interferon beta	54
Interleukin-12 antagonist	40
Interleukin-17A antagonist	58
Interleukin-23 antagonist	98
Interleukin-4 receptor alpha antagonist	99
Interleukin-5 antagonist	160
Interleukin-6 receptor antagonist	56
Janus kinase inhibitor	174
Kinase inhibitor	118
l-Thyroxine	53
Leukotriene receptor antagonist	83
Loop diuretic	50
Nonergot dopamine agonist	47
Nonsteroidal anti-inflammatory drug	128
Opioid agonist	51
P2Y12 platelet inhibitor	133
Parathyroid hormone analog	38
Phosphodiesterase 4 inhibitor	28
Progestin	25
Proton pump inhibitor	497
Retinoid	71
Selective T cell costimulation modulator	48
Somatostatin analog	124
Thalidomide analog	60
Thiazide diuretic	268
Thiazide-like diuretic	41
Tumor necrosis factor blocker	396
Vitamin K antagonist	31

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Polyp, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Polyp
Age	Reports	Share
Under 2	3	under 0.1%
2 to 11	22	0.3%
12 to 17	41	0.6%
18 to 44	448	6.9%
45 to 64	1,674	26%
65 to 74	1,061	16.5%
75 and over	593	9.2%
Age not given	2,607	40.4%

Sex of the patient in the reports that record Polyp
Sex	Reports	Share
Female	3,577	55.5%
Male	2,181	33.8%
Unknown or not given	691	10.7%

Age and sex are as the report gives them. 61.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Polyp: adverse event reports that record this term. https://reportedreactions.com/reaction/polyp/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Polyp mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page